Q32 Bio Inc. Their mission is to re-balance the immune system by creating drugs that target influential regulators of both the innate and adaptive immune systems. With a focus on transforming the lives of patients with immune diseases, Q32 Bio has assembled a team of exceptionally skilled professionals, including scientists, immunologists, and drug developers, who are fully committed to their cause.

Q32 Bio's exciting pipeline consists of two clinical-stage, investigational products currently undergoing evaluation in clinical trials. ADX-097, their innovative Innate System Modulator, is a tissue-targeted complement inhibitor. This drug is currently being studied in a Phase 1, first-in-human trial, with the objectives of assessing safety and proof of mechanism.

The trial is expected to be completed in the first half of 2023. Additionally, Q32 Bio is developing ADX-914, an Adaptive System Modulator that specifically targets the IL-7 receptor α. This drug is currently in a Phase 2 study involving patients with atopic dermatitis.

With their headquarters located in Waltham, MA, Q32 Bio is poised to revolutionize the future of targeted immune therapeutics. By leveraging their expertise and innovative research in biotherapeutics, Q32 Bio is committed to making a significant impact on the lives of patients and improving the field of immune disease treatment